AstraZeneca Delays Data Readout for Phase 3 Trial of Lung Cancer Combination Treatment

03:06 AM EDT, 10/27/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) updated the expected data readout timing for the late-stage Pacific-9 study to the first half of 2027 from the previous second half of 2026 schedule, according to a Tuesday release. The AstraZeneca-led trial is evaluating durvalumab plus monalizumab or oleclumab as a treatment for unresectable stage 3 non-small cell lung cancer that has not yet progressed after platinum-based chemoradiation therapy. Innate Pharma (IPH.PA) and AstraZeneca are jointly developing monalizumab. The Paris-listed biotechnology company said the delay was due to the event-driven nature of the study.